Back

Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis

1 September 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Treatment of transthyretin amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Theodoros Tsampras

National & Kapodistrian University of Athens Medical School, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies
Doctor M. Rahman (Flushing, US)
Abstract Slides Video
Presentation thumbnail
Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry
Doctor L. Schmid (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
Doctor F. Cappelli (Florence, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of transthyretin amyloidosis

The Event

Event poster

ESC Congress 2025

1 September 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.
thumbnail
Congress Presentation
Disease-modifying treatments in transthyretin amyloid cardiomyopathy: a meta-analysis of randomized controlled trials
thumbnail
Congress Presentation
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources